Skip to main content
Journal cover image

Acetyl-CoA metabolism drives epigenome change and contributes to carcinogenesis risk in fatty liver disease.

Publication ,  Journal Article
Assante, G; Chandrasekaran, S; Ng, S; Tourna, A; Chung, CH; Isse, KA; Banks, JL; Soffientini, U; Filippi, C; Dhawan, A; Liu, M; Rozen, SG ...
Published in: Genome Med
June 23, 2022

BACKGROUND: The incidence of non-alcoholic fatty liver disease (NAFLD)-associated hepatocellular carcinoma (HCC) is increasing worldwide, but the steps in precancerous hepatocytes which lead to HCC driver mutations are not well understood. Here we provide evidence that metabolically driven histone hyperacetylation in steatotic hepatocytes can increase DNA damage to initiate carcinogenesis. METHODS: Global epigenetic state was assessed in liver samples from high-fat diet or high-fructose diet rodent models, as well as in cultured immortalized human hepatocytes (IHH cells). The mechanisms linking steatosis, histone acetylation and DNA damage were investigated by computational metabolic modelling as well as through manipulation of IHH cells with metabolic and epigenetic inhibitors. Chromatin immunoprecipitation and next-generation sequencing (ChIP-seq) and transcriptome (RNA-seq) analyses were performed on IHH cells. Mutation locations and patterns were compared between the IHH cell model and genome sequence data from preneoplastic fatty liver samples from patients with alcohol-related liver disease and NAFLD. RESULTS: Genome-wide histone acetylation was increased in steatotic livers of rodents fed high-fructose or high-fat diet. In vitro, steatosis relaxed chromatin and increased DNA damage marker γH2AX, which was reversed by inhibiting acetyl-CoA production. Steatosis-associated acetylation and γH2AX were enriched at gene clusters in telomere-proximal regions which contained HCC tumour suppressors in hepatocytes and human fatty livers. Regions of metabolically driven epigenetic change also had increased levels of DNA mutation in non-cancerous tissue from NAFLD and alcohol-related liver disease patients. Finally, genome-scale network modelling indicated that redox balance could be a key contributor to this mechanism. CONCLUSIONS: Abnormal histone hyperacetylation facilitates DNA damage in steatotic hepatocytes and is a potential initiating event in hepatocellular carcinogenesis.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Genome Med

DOI

EISSN

1756-994X

Publication Date

June 23, 2022

Volume

14

Issue

1

Start / End Page

67

Location

England

Related Subject Headings

  • Non-alcoholic Fatty Liver Disease
  • Mice, Inbred C57BL
  • Mice
  • Liver Neoplasms
  • Liver
  • Humans
  • Histones
  • Fructose
  • Epigenome
  • Diet, High-Fat
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Assante, G., Chandrasekaran, S., Ng, S., Tourna, A., Chung, C. H., Isse, K. A., … Youngson, N. A. (2022). Acetyl-CoA metabolism drives epigenome change and contributes to carcinogenesis risk in fatty liver disease. Genome Med, 14(1), 67. https://doi.org/10.1186/s13073-022-01071-5
Assante, Gabriella, Sriram Chandrasekaran, Stanley Ng, Aikaterini Tourna, Carolina H. Chung, Kowsar A. Isse, Jasmine L. Banks, et al. “Acetyl-CoA metabolism drives epigenome change and contributes to carcinogenesis risk in fatty liver disease.Genome Med 14, no. 1 (June 23, 2022): 67. https://doi.org/10.1186/s13073-022-01071-5.
Assante G, Chandrasekaran S, Ng S, Tourna A, Chung CH, Isse KA, et al. Acetyl-CoA metabolism drives epigenome change and contributes to carcinogenesis risk in fatty liver disease. Genome Med. 2022 Jun 23;14(1):67.
Assante, Gabriella, et al. “Acetyl-CoA metabolism drives epigenome change and contributes to carcinogenesis risk in fatty liver disease.Genome Med, vol. 14, no. 1, June 2022, p. 67. Pubmed, doi:10.1186/s13073-022-01071-5.
Assante G, Chandrasekaran S, Ng S, Tourna A, Chung CH, Isse KA, Banks JL, Soffientini U, Filippi C, Dhawan A, Liu M, Rozen SG, Hoare M, Campbell P, Ballard JWO, Turner N, Morris MJ, Chokshi S, Youngson NA. Acetyl-CoA metabolism drives epigenome change and contributes to carcinogenesis risk in fatty liver disease. Genome Med. 2022 Jun 23;14(1):67.
Journal cover image

Published In

Genome Med

DOI

EISSN

1756-994X

Publication Date

June 23, 2022

Volume

14

Issue

1

Start / End Page

67

Location

England

Related Subject Headings

  • Non-alcoholic Fatty Liver Disease
  • Mice, Inbred C57BL
  • Mice
  • Liver Neoplasms
  • Liver
  • Humans
  • Histones
  • Fructose
  • Epigenome
  • Diet, High-Fat